Clik here to view.
Novogene and Illumina to Co-Develop NGS Diagnostic System for Reproductive...
BEIJING & SAN DIEGO Novogene, a leading global provider of genomic services and solutions, and Illumina, Inc. (NASDAQ: ILMN) today announced they have entered into an agreement to jointly...
View ArticleClik here to view.
bioAffinity Technologies Announces Patent Award in China
SAN ANTONIO bioAffinity Technologies announced the People’s Republic of China has awarded a Certificate of Invention Patent for the Company’s proprietary CyPath® assay, a bio-label that...
View ArticleClik here to view.
京都大学iPS細胞研究所（CiRA）と武田薬品のiPS細胞研究に関する共同研究（T-CiRA）の開始について
京都 & 大阪 （ビジネスワイヤ） — 京都大学iPS細胞研究所（所在地：京都市左京区、以下「CiRA」（サイラ））と武田薬品工業株式会社（本社：大阪市中央区、以下「武田薬品」）は、このたび、iPS細胞技術の臨床応用に向けた共同研究を開始しましたのでお知らせします。Takeda-CiRA Joint Program for iPS Cell...
View ArticleClik here to view.
Kyoto University’s Center for iPS Cell Research Application and Takeda Launch...
KYOTO & OSAKA, Japan The Center for iPS Cell Research and Application (CiRA) at Kyoto University and Takeda Pharmaceutical Company Limited (Takeda) announced today the initiation of the joint...
View ArticleClik here to view.
初発膠芽腫を治療するためのオプチューンとテモゾロミドの併用を検討したピボタル第3相試験のデータをAmerican Medical Association...
ジャージー島セントヘリア （ビジネスワイヤ） — ノボキュア（NASDAQ:...
View ArticleClik here to view.
Pharmaron Receives a CFDA GLP Certificate for its Safety Assessment Facility
BEIJING Pharmaron announced today that the company has received a Certificate of GLP Compliance, covering genetic toxicology and reproductive toxicology (DART Segments I and II), from the Chinese...
View ArticleClik here to view.
Clik here to view.
Takeda Announces Sale of Respiratory Portfolio to AstraZeneca
OSAKA, Japan Takeda Pharmaceutical Company Limited (TOKYO:4502) today announced that it has entered into a definitive agreement to sell its respiratory portfolio to AstraZeneca. In 2014 Takeda...
View ArticleClik here to view.
京都大学iPS细胞研究及应用中心与武田合作，在湘南研究中心(T-CiRA)联合开展 iPS 细胞应用研究项目
日本京都和大阪 (美国商业资讯) — 京都大学iPS细胞研究及应用中心(CiRA)与武田药品工业株式会社（武田）今天宣布，启动开发多能诱导干细胞临床应用的合作研究项目。“武田-CiRA iPS细胞应用合作项目”(T-CiRA)将在六个核心方向开始研究，以探索干细胞在癌症、心力衰竭、糖尿病、神经退行性疾病和难治性肌肉疾病等治疗领域的临床应用。 Smart News...
View ArticleClik here to view.
康龙化成的安全性评估设施获得CFDA GLP认证
北京 (美国商业资讯)–康龙化成今天宣布，该公司设在北京的GLP安全性评估设施已获得中国国家食品药品监督管理局(CFDA)的GLP合规认证，认证范围覆盖基因毒理学和生殖毒理学（DART Segments I 和 II）。这是该设施自2013年以来从CFDA获得的第二个GLP合规认证。据此，康龙化成能够向合作伙伴提供IND报批的全套安全性评估服务，以支持他们向CFDA报批IND。...
View ArticleClik here to view.
武田宣布将呼吸产品线出售给阿斯利康
日本大阪 (美国商业资讯) — 武田药品工业株式会社(TOKYO:4502)今天宣布已签署一份将呼吸产品线出售给阿斯利康的确定性协议。2014年武田确定了四个重点治疗领域：胃肠病、肿瘤、中枢神经系统、心血管及代谢。此次业务剥离将使武田为成为这些治疗领域的业界翘楚而努力，同时保持患者治疗的连续性。 武田药品工业株式会社首席执行官Christophe...
View ArticleClik here to view.
Gore RELINE MAX臨床試験に最初の患者を組み入れ
米アリゾナ州フラッグスタッフ （ビジネスワイヤ） — W. L. Gore & Associates（ゴア）は、Gore RELINE MAX臨床試験に最初の患者が組み入れられたことを発表します。本試験は、浅大腿動脈（SFA）におけるステント内再狭窄の治療を目的とするGORE® VIABAHN® Endoprosthesis with Heparin Bioactive...
View ArticleClik here to view.
Gore RELINE MAX临床研究入组首例患者
亚利桑那州弗拉格斯塔夫 (美国商业资讯) — W. L. Gore & Associates (Gore) 宣布，Gore RELINE MAX临床研究现在入组首例患者，该上市后研究继续评估拥有肝素生物活性涂层的GORE® VIABAHN®内假体用于治疗股浅动脉(SFA)支架内再狭窄。原先的Gore RELINE临床研究结果支持了FDA于2014年对于GORE...
View ArticleClik here to view.
サンバイオと大日本住友製薬：脳梗塞治療剤SB623の北米第Ⅱb相臨床試験における被験者募集開始のお知らせ
東京 （ビジネスワイヤ） – サンバイオ株式会社（本社：東京都中央区、社長：森 敬太）と大日本住友製薬株式会社（本社：大阪市、社長：多田 正世、以下「大日本住友製薬」）は、サンバイオ株式会社の子会社であるSanBio,...
View ArticleClik here to view.
PeptiDream Announces Peptide Discovery Collaboration Agreement with Genentech
TOKYO PeptiDream Inc., a public Tokyo-based biopharmaceutical company (“PeptiDream”)(TOKYO:4587) today announced a multi-target discovery and optimization collaboration with US-based Genentech Inc.,...
View ArticleClik here to view.
Blue Belt Technologies Announces the First Robotics-Assisted Partial Knee...
MINNEAPOLIS Blue Belt Technologies, a medical technology company specializing in robotic solutions for orthopedic surgery, announced the first Navio-assisted surgery performed in Australia utilizing...
View ArticleClik here to view.
ReproCELL Announced: A Joint Development with the National Cancer Center
YOKOHAMA, Japan ReproCELL, Inc. (JASDAQ:4978): “ReproHP Medium,” a highly functional culture fluid for human primary liver cells developed in conjunction with the National Cancer Center, is set to...
View ArticleClik here to view.
Clik here to view.
Takeda Provides Further Information about its New Business Venture with Teva
OSAKA, Japan & Jerusalem Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Takeda Pharmaceutical Company Limited (TSE: 4502) today made the below follow-up announcement regarding the...
View ArticleClik here to view.
INSERTING and REPLACING Takeda Provides Further Information about its New...
OSAKA, Japan & Jerusalem Insert after 1st sentence in last bullet of release: The new business venture will be instantly accretive to Teva’s non GAAP EPS in 2016 and beyond. The corrected...
View Article